References in periodicals archive ?
Predictors for malignant tissue (MT) in residual masses (RM) of non-seminomatous germ cell tumours (NSGCT) treated by chemotherapy (CT) before surgery.
For all stage II NSGCT with elevated tumor markers, platinum-based chemotherapy is recommended as the initial treatment after orchiectomy (standard: EP, 4 cycles, or BEP, 3 cycles).
Seminoma was diagnosed in 283 men (54.1%), nonseminomatous germ cell tumors (NSGCT) in 240 men (45.9%).
One hundred and twenty patients with NSGCT were identified.
The management of seminoma is less clear and may be more controversial than that for NSGCT. (20) In seminoma, tumor markers may be negative at presentation (as was the case with our patient) and there fore may not be available to guide therapy.
A complementary paper on NSGCT in the AYA population investigated the SEER database to evaluate the association between age and outcomes .
Additionally, a contemporary cohort of control patients (n = 32) were identified who had NSGCT diagnosed as pT2 because of the presence of LVI confined to the testis without LVI present in the spermatic cord.
The current active surveillance protocol for CSI NSGCT at Princess Margaret involves regular and structured monitoring of tumour markers (alpha-fetoprotein [AFP], human chorionic gonadotropin [hCG], lactate dehydrogenase [LDH]) and computed tomography (CT) scans of the chest, abdomen, and pelvis, and has been previously outlined in the literature.
Germ cell tumors ACBI (b) AJCC EAU EGTM (53) (28) (22) (10, 21) AFP and hCG for Screening N N Diagnosis/case-finding Y Y Staging/prognosis Y Y Y Y Detecting recurrence Y Y Y Monitoring therapy Y Y Y AFP for differential Y Y diagnosis of NSGCT LDH for Diagnosis/case-finding Y Y Staging/prognosis Y Y Detecting recurrence Y Y Monitoring therapy Y Y ESMO NACB SIGN (54, 55) (9, 10) (18) AFP and hCG for Screening N N N Diagnosis/case-finding Y Y Y Staging/prognosis Y Y Y Detecting recurrence Y Y Y Monitoring therapy Y Y Y AFP for differential Y Y diagnosis of NSGCT LDH for Diagnosis/case-finding Y Y Y Staging/prognosis Y Y Y Detecting recurrence Y Y Y Monitoring therapy Y Y Y B.
reported upon 191 cases of pathologic node-positive cases undergoing primary RPLND for early stage NSGCT .
Following orchiectomy, progression occurs in approximately 30% of patients with clinical stage I (CSI) non-seminoma germ cell tumours (NSGCT) and approximately 15% of patients with CSI seminoma.
Germ cell tumours comprise the predominant histology in testicular cancer  and are broadly categorized into seminoma and nonseminomatous germ cell tumours (NSGCT) due to differences in management and prognosis.
Acronyms browser ?
Full browser ?